In the era of highly active antiretroviral therapy, why are HIV‐infected patients still admitted to hospital for an inaugural opportunistic infection?

To identify factors related to delayed testing, and delayed or interrupted care‐seeking or treatment uptake, among HIV‐infected patients.

[1]  J. Bartlett.  Decline in the AIDS and Death Rates in the EuroSIDA study: An observational study , 2004 .

[2]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[3]  Frederick M. Hecht,et al.  HIV Testing Within At‐Risk Populations in the United States and the Reasons for Seeking or Avoiding HIV Testing , 2002, Journal of acquired immune deficiency syndromes.

[4]  O. Kirk,et al.  Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy , 2002, Annals of Internal Medicine.

[5]  Michael S Saag,et al.  Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.

[6]  J. Moatti,et al.  Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. , 2002, Social science & medicine.

[7]  A. Mocroft,et al.  Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy , 2001 .

[8]  C. Pradier,et al.  Factors related to delayed diagnosis of HIV infection in southeastern France , 2000, International journal of STD & AIDS.

[9]  A. Mocroft,et al.  AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.

[10]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.

[11]  David R. Holtgrave,et al.  Promoting early HIV diagnosis and entry into care. , 1999, AIDS.

[12]  A. Haworth,et al.  HIV counselling and testing: overemphasizing high acceptance rates a threat to confidentiality and the right not to know. , 1999, AIDS.

[13]  J A Fleishman,et al.  Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. , 1999, JAMA.

[14]  A. Telenti,et al.  Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. , 1999, Journal of acquired immune deficiency syndromes.

[15]  D. Rimland,et al.  Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia. , 1999, AIDS.

[16]  K. Sepkowitz,et al.  The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. , 1999, AIDS.

[17]  D. McCaffrey,et al.  The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. , 1998, The New England journal of medicine.

[18]  D. Jeffe,et al.  Factors associated with HIV-infected patients' recognition and use of HIV medications. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[19]  A. Moorman,et al.  Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients , 1998 .

[20]  R. Coutinho,et al.  HIV surveillance among sexually transmitted disease clinic attenders in Amsterdam, 1991–1996 , 1998, AIDS (London).

[21]  P. Morlat,et al.  Determinants of delayed diagnosis of HIV infection in France, 1993–1995 , 1998, AIDS.

[22]  P. Bossi,et al.  Caractéristiques épidémiologiques des toxoplasmoses cérébrales chez 399 patients infectés par le VIH suivis entre 1983 et 1994 , 1998 .

[23]  C. Katlama,et al.  [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994]. , 1998, La Revue de medecine interne.

[24]  K. Freedberg,et al.  Trillion virion delay: time from testing positive for HIV to presentation for primary care. , 1998, Archives of internal medicine.

[25]  G. Lemp,et al.  Prevention of Pneumocystis carinii pneumonia: who are we missing? , 1997, AIDS.

[26]  A. Pesce,et al.  Reducing the incidence of Pneumocystis carinii pneumonia: a persisting challenge. , 1997, AIDS.

[27]  R. Lalonde,et al.  The continued occurrence of primary Pneumocystis carinii pneumonia despite the availability of prophylaxis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  P. Kerndt,et al.  Reasons for HIV antibody test refusal in a heterosexual sexually transmitted disease clinic population , 1996, AIDS.

[29]  R. Chaisson,et al.  Communications to the EditorThe Effect of Prophylaxis on the Outcome of HIV-Associated Pneumocystis carinii Pneumonia , 1996 .

[30]  S. Ewig.  The effect of prophylaxis on the outcome of HIV-associated Pneumocystis carinii pneumonia. , 1996, Chest.

[31]  R. Chaisson,et al.  The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. , 1995, Chest.

[32]  J. Ward,et al.  Characteristics of persons with late AIDS diagnosis in the United States. , 1995, American journal of preventive medicine.

[33]  B. Evans,et al.  Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. , 1993, BMJ.

[34]  P. Hutto,et al.  HIV Seroprevalence and Reasons for Refusing and Accepting HIV Testing , 1991, Sexually transmitted diseases.

[35]  Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. , 1989, MMWR supplements.